Medical technology company Volpara
(ASX:VHT) has today entered into a full distribution agreement with AI software company ScreenPoint Medical.
The agreement allows Volpara to distribute ScreenPoint’s Transpara™ product to breast imaging clinics in Australia, New Zealand, the United States, and parts of Asia.
Volpara says combining the Volpara and Transpara solutions can optimise the early detection of breast cancer, thereby reducing radiologist liability and risk, and cutting screening costs by potentially eliminating a reader in systems that deploy double-reading mammography.
The deal is a five-year, non-exclusive contract with automatic renewal rights.
Shares in Volpara
(ASX:VHT) are trading 3.38 per cent higher at $1.68.
